MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
TSX:MBX - Toronto Stock Exchange - CA59501P1045 - Common Stock - Currency: CAD
Overall MBX gets a fundamental rating of 7 out of 10. We evaluated MBX against 24 industry peers in the Biotechnology industry. MBX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: MBX is growing strongly while it also seems undervalued. These ratings could make MBX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
MBX had positive earnings in the past year.
In the past year MBX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
Of the past 5 years MBX 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of MBX (3.97%) is better than 91.67% of its industry peers.
MBX has a better Return On Equity (5.04%) than 95.83% of its industry peers.
MBX has a better Return On Invested Capital (4.29%) than 91.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.97% | ||
| ROE | 5.04% | ||
| ROIC | 4.29% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 6.89%, MBX belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
In the last couple of years the Profit Margin of MBX has grown nicely.
MBX has a Operating Margin of 9.61%. This is amongst the best in the industry. MBX outperforms 91.67% of its industry peers.
MBX's Operating Margin has improved in the last couple of years.
MBX has a better Gross Margin (57.74%) than 87.50% of its industry peers.
MBX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.61% | ||
| PM (TTM) | 6.89% | ||
| GM | 57.74% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MBX is destroying value.
MBX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for MBX has been increased compared to 5 years ago.
Compared to 1 year ago, MBX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.30 indicates that MBX is not in any danger for bankruptcy at the moment.
MBX's Altman-Z score of 3.30 is amongst the best of the industry. MBX outperforms 91.67% of its industry peers.
The Debt to FCF ratio of MBX is 2.38, which is a good value as it means it would take MBX, 2.38 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MBX (2.38) is better than 91.67% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that MBX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.17, MBX is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 2.38 | ||
| Altman-Z | 3.3 |
ROIC/WACC0.52
WACC8.32%
2.3 Liquidity
A Current Ratio of 9.36 indicates that MBX has no problem at all paying its short term obligations.
MBX has a better Current ratio (9.36) than 91.67% of its industry peers.
A Quick Ratio of 6.37 indicates that MBX has no problem at all paying its short term obligations.
MBX has a Quick ratio of 6.37. This is amongst the best in the industry. MBX outperforms 91.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.36 | ||
| Quick Ratio | 6.37 |
3. Growth
3.1 Past
MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -44.66%.
Measured over the past years, MBX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.58% on average per year.
The Revenue has decreased by -4.65% in the past year.
MBX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.62% yearly.
EPS 1Y (TTM)-44.66%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-96.3%
Revenue 1Y (TTM)-4.65%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-5.47%
3.2 Future
The Earnings Per Share is expected to grow by 51.83% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 21.86% on average over the next years. This is a very strong growth
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MBX is valuated quite expensively with a Price/Earnings ratio of 29.50.
Based on the Price/Earnings ratio, MBX is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.41, MBX is valued at the same level.
A Price/Forward Earnings ratio of 7.30 indicates a rather cheap valuation of MBX.
MBX's Price/Forward Earnings ratio is rather cheap when compared to the industry. MBX is cheaper than 100.00% of the companies in the same industry.
MBX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.5 | ||
| Fwd PE | 7.3 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 100.00% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, MBX is valued cheaper than 91.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.44 | ||
| EV/EBITDA | 8.34 |
4.3 Compensation for Growth
MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of MBX may justify a higher PE ratio.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 51.83% in the coming years.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
MBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MBX (7/11/2025, 7:00:00 PM)
0.295
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.97%
Ins Owner ChangeN/A
Market Cap41.47M
Analysts80
Price Target0.92 (211.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.5 | ||
| Fwd PE | 7.3 | ||
| P/S | 1.82 | ||
| P/FCF | 18.44 | ||
| P/OCF | 10.55 | ||
| P/B | 1.33 | ||
| P/tB | 1.53 | ||
| EV/EBITDA | 8.34 |
EPS(TTM)0.01
EY3.39%
EPS(NY)0.04
Fwd EY13.69%
FCF(TTM)0.02
FCFY5.42%
OCF(TTM)0.03
OCFY9.48%
SpS0.16
BVpS0.22
TBVpS0.19
PEG (NY)0.59
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.97% | ||
| ROE | 5.04% | ||
| ROCE | 5.96% | ||
| ROIC | 4.29% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 8.69% | ||
| OM | 9.61% | ||
| PM (TTM) | 6.89% | ||
| GM | 57.74% | ||
| FCFM | 9.9% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-16.73%
ROICexcg growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score6
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 2.38 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 99.49% | ||
| Cap/Sales | 7.4% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.47% | ||
| Profit Quality | 143.69% | ||
| Current Ratio | 9.36 | ||
| Quick Ratio | 6.37 | ||
| Altman-Z | 3.3 |
F-Score6
WACC8.32%
ROIC/WACC0.52
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.66%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-96.3%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.65%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-5.47%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y59.46%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-29.47%
EBIT Next 3Y21.52%
EBIT Next 5YN/A
FCF growth 1Y310.13%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y260.45%
OCF growth 3Y27.25%
OCF growth 5Y155.41%